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Abstract
Background Previous studies have demonstrated that the
administration of antibiotics to patients before performing
diagnostic testing for periprosthetic joint infection (PJI)
can interfere with the accuracy of test results. Although a
single-institution study has suggested that alpha-defensin
maintains its concentration and sensitivity even after
antibiotic treatment, this has not yet been demonstrated in a
larger multiinstitutional study.
Questions/purposes (1) For the evaluation of PJI, is prior
antibiotic administration associated with decreased alpha-
defensin levels? (2) When prior antibiotics are given, is
alpha-defensin a better screening test for PJI than the tra-
ditional tests (erythrocyte sedimentation rate [ESR], C-
reactive protein [CRP], fluid white blood cells, fluid
polymorphonuclear cells [PMNs], and fluid culture)?
Methods This retrospective study included data from 106
hip and knee arthroplasties with Musculoskeletal Infection
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Society-defined PJI from four centers. Of the 106 patients
in this study, 30 (28%) were treated with antibiotics for PJI
before diagnostic workup (ABX group), and 76 (72%)
were not treated before the diagnostic workup (NO-ABX
group). There were no differences in age, sex, joint, cul-
ture-negative rate, or bacteriology between groups. The
patients in the ABX group had antibiotics initiated by
physicians who commenced care before assessment for PJI
by the treating surgeon’s service. We compared the alpha-
defensin levels and sensitivity between the ABX and NO-
ABX groups. Additionally, the sensitivity of the alpha-
defensin test was compared to that of traditional tests for
PJI among patients on antibiotics.
Results The administration of antibiotics before perform-
ing the alpha-defensin test for PJI was not associated with a
decreased median alpha-defensin level (ABX group, median
4.2 [range, 1.79–12.8 S/CO] versus NO-ABX, median 4.9
[range, 0.5–16.8 S/CO], difference of medians: 0.68 S/CO
[95% confidence interval {CI}, 0.98 to 1.26], p = 0.451).
Furthermore, the alpha-defensin test had a higher sensitivity
(100%; 95% CI, 88.4%–100.0%) in diagnosing PJI among
patients on antibiotics when compared with the ESR (69.0%
[95% CI, 49.17%–84.72%], p = 0.001), the CRP (79.3%
[95% CI, 60.3%–92.0%], p = 0.009), the fluid PMN%
(79.3% [95% CI, 60.3%–92.0%), p = 0.009), and fluid
culture (70.0% [95% CI, 50.6%–85.3%], p = 0.001).
Conclusions The alpha-defensin test maintains its con-
centration and sensitivity for PJI even in the setting of
antibiotic administration. Furthermore, among patients
with PJI on antibiotics, the alpha-defensin tests demon-
strated a higher sensitivity in detecting PJI when compared
with the ESR, CRP, fluid PMN%, and fluid culture. The
high sensitivity of the alpha-defensin test, even in the
setting of prior antibiotic treatment, provides excellent
utility as a screening test for PJI.
Level of Evidence Level III, diagnostic study.
Introduction
In the absence of major criteria such as a communicating
sinus tract or two positive cultures, clinicians must rely on
laboratory values to diagnose periprosthetic joint infection
(PJI) [12]. We have previously demonstrated that prema-
ture antibiotic administration can compromise the
sensitivity of traditional diagnostic laboratory results [13].
To increase the sensitivity of traditional diagnostic tests,
the clinical practice guideline of the American Academy of
Orthopaedic Surgeons recommends withholding antimi-
crobials for at least 2 weeks before aspiration of the joint
[7]. Nevertheless, patients with possible PJI are often
administered antibiotics before the treating surgeon has
been consulted to initiate a diagnostic workup.
The alpha-defensin test has shown promising results for
diagnosing PJI, as several independent institutions have
demonstrated that the overall sensitivity and specificity of
the alpha-defensin test is greater than 95% [2, 5, 8]. While
the accuracy of the serum erythrocyte sedimentation rate
(ESR), serum C-reactive protein, synovial fluid white blood
cell (WBC) count, and polymorphonuclear (PMN) per-
centage tests are diminished in the setting of prior
antibiotic administration [13], the sensitivity of the bio-
marker-based alpha-defensin test does not appear to be
impacted [5]. However a larger multi-institutional study
has not yet demonstrated the comparative alpha-defensin
levels and sensitivity among patients treated with or
without antibiotics before diagnostic testing.
We therefore asked: (1) For the evaluation of PJI, is
prior antibiotic administration associated with decreased
alpha-defensin levels? (2) When prior antibiotics are given,
is alpha-defensin a better screening test for PJI than the
traditional tests (erythrocyte sedimentation rate [ESR], C-
reactive protein [CRP], fluid white blood cells [WBCs],
fluid polymorphonuclear cells [PMNs], and fluid culture)?
Materials and Methods
This retrospective diagnostic study was approved by the
institutional review board. Four institutions collected syn-
ovial fluid, between October 2009 and July 2014, to study
the diagnostic profile of the alpha-defensin test. Of 498
clinically annotated synovial fluid samples retrospectively
identified as having an alpha-defensin test completed, 113
samples met the criteria for PJI and 385 samples did not
meet the criteria for PJI. Inclusion required (1) the presence
of a total joint arthroplasty; (2) sufficient data to categorize
by the Musculoskeletal Infection Society (MSIS) criteria
for PJI (Table 1); and (3) testing for alpha-defensin.
Although some patients were missing individual laboratory
tests used in the MSIS criteria for PJI, all patients in the
study had sufficient laboratory results to meet the MSIS
criteria for PJI. Patients with early postoperative PJI (4
weeks) were excluded, because synovial and serologic
markers are not reliable parameters for the diagnosis of PJI
in this setting [1, 11].
For the purposes of this specific study, we queried the
clinical and electronic records of the 113 patients with PJI
to determine whether intravenous and/or oral antibiotics
were administered within 2 weeks before the diagnostic
workup (joint aspiration and serologic marker measure-
ments) for PJI. The records for seven patients were
incomplete, leaving 106 patients included in this study. The
mean patient age was 65 years including 41 women and 65
men. The synovial fluid samples were aspirated from 77
TKAs and 29 THAs.
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Based on the antibiotic administration status, patients
were allocated into two groups. The ABX (antibiotics)
group includes patients who received antibiotics within 2
weeks before the diagnostic workup and the NO-ABX
group includes patients who did not receive antibiotics
before the diagnostic workup. Of the 106 patients with PJI
included in this study, 30 (28%) patients comprised the
ABX group and 76 (72%) patients comprised the NO-ABX
group (Table 2). The patients in the ABX group were
placed on antibiotics by a variety of emergency room
physicians, primary medical physicians, and orthopaedic
surgeons before being evaluated and tested by the treating
surgeon’s service. Therefore, we were not able to ascertain
the reasons for prediagnostic commencement of antibiotic
administration. We were also unable to specify the par-
ticular antibiotic, dosage, or timing for these patients given
that these details were spread among many hospitals near
those included in this study. It is the general policy of all
four institutions participating in this study to initiate a
diagnostic workup before antibiotic treatment begins.
As expected, the majority of the isolated organisms in
this study were Gram-positive bacteria including Staphy-
lococcus aureus and Staphylococcus epidermidis. Overall
32% (34 of 106) of the patients in our cohort had culture-
negative PJI, as defined by the MSIS criteria.
The demographic data between the ABX and NO-ABX
groups did not demonstrate any significant differences.
Specifically, there was no difference in age, sex, gender,
culture-negative rate, or bacteriology between groups
(Table 2).
The synovial fluid alpha-defensin level, ESR, CRP, fluid
WBCs, and fluid PMN% were recorded for each patient.
The median for each test was calculated for both groups.
Additionally, the sensitivities of the tests were calculated
using the MSIS criteria cutoff values as a standard to define
the presence or absence of PJI (Table 1) [12].
Statistical Analysis
Descriptive statistics were used to report all laboratory
values. The one-tailed Mann-Whitney test (Prism; Graph-
Pad Software, La Jolla, CA, USA) was used to determine
whether the median laboratory value of any given test was
significantly lower in the setting of prior antibiotic treat-
ment as well as the 95% confidence interval between the
Table 1. Definition of PJI according to the ICM workgroup and the threshold for the minor diagnostic criteria
PJI is present when one of the major criteria or three out of five minor criteria exist:
Major criteria (1) Two positive periprosthetic cultures with phenotypically identical microorganism OR









(2) Elevated SF WBC count OR
Changes in the leukocyte esterase strip
3000 cells/lL
+ Or ++
(3) Elevated SF PMN% 80%
(4) Positive histological analysis of the periprosthetic tissue [5 neutrophil per high-power field in 5 high-power fields (9400)
(5) A single positive culture
PJI = periprosthetic joint infection; ICM = International Consensus Meeting; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate;
SF = synovial fluid; WBC = white blood cell; PMN = polymorphonuclear cells.











Gender 10 women, 20 men 31 women, 45 men 0.514
Joint (knee/hip) 21 knees/9 hips 56 knees/20 hips 0.809
Gram (+) organism (%) 71% (15/21) 76% (39/51) 0.156
Culture-negative PJI 30% (9/30) 33% (25/76) 0.172
ABX = antibiotics; PJI = periprosthetic joint infection
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difference. The two-tailed Fisher’s exact test was used to
determine how the sensitivity of the alpha-defensin test
compared with the sensitivity of ESR, CRP, fluid WBC,
fluid PMN%, and culture in the setting of antibiotics. A p
value of\ 0.05 was considered statistically significant. A
post hoc power analysis including the number of patients in
this study was performed. The study has 80% power, at an
alpha of 0.05, to identify a difference of 1.92 S/CO alpha-
defensin level.
Results
The administration of antibiotics before performing the
alpha-defensin test for PJI was not associated with a
decrease in the median alpha-defensin level (ABX group,
median 4.2 [range, 1.8–12.8 S/CO] versus NO-ABX,
median 4.9 [range, 0.5–16.8 S/CO], difference of medians
0.68 S/CO [95% confidence interval {CI}, 0.98 to 1.26],
p = 0.451, Fig. 1). Likewise, there was no associated
decrease in the median ESR (ABX group, median 62
[range, 3–140 mm/hr] versus NO-ABX, median 65 [range,
1–140 mm/hr]; difference of medians 3 mm/hr [95% CI,
11 to 22 mm/hr, p = 0.252). However, the administration
of antibiotics before diagnostic testing was associated with
a decrease of the median CRP (25.7 mg/L [range, 1–302] in
the ABX group versus 62.0 mg/L [range, 3–535) in the
NO-ABX group; difference of medians 36.3, p = 0.008),
the fluid WBCs (17,325 cells/lL [range, 413–104,200] in
the ABX group versus 29,404 cells/lL [range, 1100–
356,000] in the NO-ABX group; difference of medians =
12,079, p = 0.008), and PMN% (87% [range, 3–100] in the
ABX group versus 92% [range, 40–100] in the NO-ABX
group; difference of medians 5, p = 0.034) (Table 3).
The alpha-defensin test had improved sensitivity (100%;
95% CI, 88.4%–100.0%) among patients who were treated
with antibiotics before diagnostic testing for PJI when
compared with the ESR (69.0% [95% CI, 49.17%–
84.72%], p = 0.001), the CRP (79.3% [95% CI, 60.3%–
92.0%], p = 0.009), the fluid PMN% (79.3% [95% CI,
60.3%–92.0%], p = 0.009), and fluid culture (70.0% [95%
CI, 50.6%–85.3%], p = 0.001) (Fig. 2). There was no dif-
ference when compared with the sensitivity of the fluid
WBCs (93.1% [95% CI, 77.2%–99.2%], p = 0.147).
Discussion
Our previous study showed that the traditional diagnostic
tests for PJI can be compromised by premature antibiotic
administration [13]. Although numerous studies have
demonstrated that the synovial fluid alpha-defensin test is
likely the most accurate single test for PJI [3, 4, 6, 9], only
one single-institution study has suggested that antibiotic
treatment is not associated with a decrease in alpha-de-
fensin sensitivity. The goal of our multiinstitution study
was to ascertain whether antibiotic treatment before diag-
nostic testing would be associated with decreased alpha-







Difference (95% CI) p value
Alpha-defensin (S/CO) 4.2 (1.8–12.8) 4.9 (0.5–16.8) 0.68 (0.98 to 1.26) 0.451
ESR (mm/hr) 62 (3–140) 65 (1–140) 3 (11 to 22) 0.252
CRP (mg/L) 25.7 (1.0–302) 62.0 (3.0–535) 36.3 (4.0–56.2) 0.008*
WBC (cells/lL) 17,325 (413–104,200) 29,404 (1100–356,000) 12,079 (1915–22,650) 0.008*
PMN (%) 87 (3–100) 92 (40–100) 5.0 (0.0–7.0) 0.034*
*Statistical significance; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; WBCs = white blood cells; PMN = polymor-
phonuclear; ABX = antibiotics; CI = confidence interval.
Fig. 1 The alpha-defensin levels are graphed on a logarithmic scale
for patients in the ABX and NO-ABX groups. The red line marks the
positive threshold for the alpha-defensin test (signal/cutoff = 1). The
black lines denote median group values with interquartile ranges.
ABX = antibiotics group; NO-ABX = no antibiotics group; S/CO =
signal-to-cutoff ratio.
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defensin sensitivity and to compare this sensitivity with
other traditional tests for PJI.
There are several limitations to our study and our find-
ings should be interpreted in light of these shortcomings.
Many patients were referred to the tertiary care centers in
this study and did not have detailed accompanying infor-
mation regarding the start date or rationale behind the
initiation of antibiotics. It would have been ideal to eval-
uate the rationale for antibiotic initiation and the duration
of treatment in relation to the results in this study.
Although we were able to demonstrate no difference
between certain demographic characteristics in the two
groups, there is always a possibility that an unknown fac-
tor, other than antibiotic treatment, caused some of the
diagnostic differences identified in this study. Another
limitation relates to the use of the MSIS criteria for PJI. It
is possible that some patients with PJI do not meet the
MSIS criteria, which would have resulted in a failure to
include them in this study. We believe that this population
of patients with a false-negative MSIS result is likely very
small and would not have perturbed our current results.
Additionally, we only assessed patients with PJI to assess
the sensitivity of alpha-defensin and did not intend to
assess specificity with and without antibiotics. Finally,
patients were identified from four institutions based on
having had an alpha-defensin test request, and seven of 113
identified patients were excluded as a result of incomplete
medical records. It is certainly possible, as a result of the
circumstances of admitting patients with PJI to the hospital,
that some PJIs cared for by this study’s investigators were
not recruited for this study. Although we cannot assess how
many patients were not included, we have no reason to
believe that there was any selection bias in the population
of patients included in this study.
Our multiinstitution study demonstrates that the initia-
tion of antibiotic treatment for PJI before diagnostic
evaluation does not appear to be associated with decreases
in the median alpha-defensin levels. In fact, the consistency
of the median alpha-defensin level in this study was
observed among a population of patients on antibiotics who
simultaneously demonstrated a decreased median CRP,
fluid WBCs, and fluid PMNs. These results corroborate the
single-institution findings of Deirmengian et al. [5], who
did not observe any effect of prior antibiotic treatment on
alpha-defensin levels or sensitivity. They also corroborate
the results of a previous study demonstrating the fact that
many traditional tests for PJI have lower mean levels
among patients with PJI who started antibiotic treatment
before diagnostic testing [13]. Although it is possible that a
higher powered study may demonstrate a statistically sig-
nificant difference in alpha-defensin levels among those on
antibiotics, the small absolute difference identified in this
study would require a study of over 8000 PJIs to demon-
strate that this difference is statistically significant.
This study also found that when screening for PJI in the
setting of antibiotic use, alpha-defensin is more sensitive
than the ESR, CRP, fluid PMN%, and fluid culture. Given
the numbers in this study, we did not find a statistically
significant improvement over the fluid WBCs. The
importance of any screening test lies in its ability to
identify disease reliably, thus having a high sensitivity.
Several previous studies have demonstrated the sensitivity
of the alpha-defensin test to be greater than 95%. Deir-
mengian et al. [6] reported that the alpha-defensin levels
were consistent results regardless of the organism type,
Gram type, species, or virulence of the organism. In
another study by Bingham et al. [2], the authors concluded
that the sensitivity and specificity of the synovial fluid
alpha-defensin assay exceeded the sensitivity and speci-
ficity of other currently available clinical tests. In this study
we extend the utility of the alpha-defensin test to screening
those patients who were started on antibiotic treatment
before diagnostic testing. The appropriate use of the alpha-
defensin test remains to be definitively established. One
might suggest that the alpha-defensin test should only be
used when traditional tests fail to provide a clear diagnosis,
promoting cost-effectiveness. On the other hand, the alpha-
defensin test has been consistently demonstrated by several
institutions to be the most sensitive and specific individual
test for PJI [2, 9, 10] and also has a negligible cost relative
to the care of PJI (approximately USD 31 reimbursement
by the Centers for Medicare & Medicaid Services for the
laboratory-based Synovasure PJI test; CD Diagnostics,
Claymont, DE, USA). Selective utilization of the alpha-
Fig. 2 Comparison of diagnostic sensitivities of laboratory tests
among patients treated with antibiotics before diagnostic testing for
PJI. The asterisks denote tests that demonstrated a statistically
significant lower sensitivity when compared with the alpha-defensin
sensitivity.
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defensin test only after receiving traditional test results
would require reaspiration of the joint and presupposes the
ability to differentiate between clear and ambiguous cases
of PJI, which is likely not consistent among surgeons. The
appropriate use of the alpha-defensin test in practice is
currently being defined by individual institutions.
In summary, our study demonstrates that alpha-defensin
maintains its synovial fluid levels even when patients are
treated with antibiotics before a diagnostic workup. Addi-
tionally, among patients treated with antibiotics before
diagnostic testing, the alpha-defensin test had a higher
sensitivity and provided better screening for PJI than the
ESR, CRP, fluid PMN%, and fluid culture.
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